Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) Release: ELIQUIS® (apixaban) Receives CHMP Positive Opinion for the Prevention Of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation
9/21/2012 10:12:08 AM
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that ELIQUIS® (apixaban) be granted approval for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) and one or more risk factors for stroke. The CHMP's positive opinion will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. The final decision will be applicable to all 27 European Union member states plus Iceland and Norway.